Pharmaceutical products generate 70% of its revenue, while veterinary products bring in 12% and TCH, 15%. Its products are mainly distributed through private clinics and hospitals.
It is in the midst of expanding its foothold in Asean.
It has a strong balance sheet with a net cash of rm24 million as at March 31 2013 and cash balances of rm53.7 million compared with borrowings of rm29.7 million.
It is still in a growth stage that required capital investment but it still sticks to the dividend policy of 50%.
No comments:
Post a Comment